Through close collaboration with the Evotec AG, European ScreeningPort can also offer access to a variety of Evotec’s Drug Discovery capabilities to its academic collaborators and thereby provides a comprehensive “Discovery Solution”. These  include:

• Screening of cellular and biochemical assays in 1,536-well and 2,080-well formats on three proprietary and fully-integrated screening systems
• Screening of GPCR targets in cellular assays on an integrated 384 well-based robotic system equipped with a FLIPR reader
• Fragment based screening 
• protein structure determination
• Hit and Lead profiling
• medicinal chemistry and lead optimisation services